Markets

Genomic Health Presents New Oncotype DX Data - Analyst Blog

A stock chart on display
Credit: Shutterstock photo

Genomic Health, Inc. ( GHDX ) reported positive data from three studies of the Oncology DX prostate cancer test, which have been published in European Urology.

The peer-reviewed publication highlights those studies which focus on addressing the need of the large share of prostate cancer patients who are candidates for active surveillance.

The results demonstrated the 17-gene Oncotype DX Genomic Prostate Score (GPS) as a significant predictor of disease aggressiveness at the time of diagnosis - before intervention with radiation or surgery. The GPS also provides more precise and customized risk assessment beyond currently available risk factors to help physicians and their prostate cancer patients confidently select the most appropriate mode of treatment.

Genomic Health has developed and validated the Oncotype DX prostate cancer test in collaboration with Cleveland Clinic and University of California, San Francisco (UCSF). The test caters to the challenges of local prostate cancer diagnosis and treatment by revealing the underlying biology of the tumor and using genes from multiple biologic pathways to predict the aggressiveness of prostate cancer, if diagnosed.

Each year, more than 210,000 U.S. men are diagnosed with prostate cancer based on their needle biopsies. However, the existing methods of examining the very small amounts of tissue obtained by needle biopsy under the microscope are not adequate and accurate enough to predict whether more aggressive disease still remains in the prostate. This limitation has led most men to decide to treat prostate cancer immediately; despite the disease having less than three percent chances of causing significant medical problems during their lifetime.

Each cancer has unique tumor biology that determines specific clinical behavior. Based on that, Genomic Health has developed tests - each with distinct genes across multiple pathways - to address the most relevant concerns of breast, colon and prostate cancer patients.

The company believes that based on the aforementioned study results, the use of GPS can potentially increase the number of men who can confidently opt for active surveillance by 20% to 30%. The ability of prostrate cancer patients to define their individual risk of aggressive disease more precisely signifies a meaningful step forward in precision cancer care.

Genomic Health currently holds a Zacks Rank #3 (Hold). Some better-ranked stocks worth considering in the med-biomed/generic industry include ANI Pharmaceuticals, Inc. ( ANIP ), Myriad Genetics Inc. ( MYGN ) and Illumina Inc. ( ILMN ). All these stocks carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

GENOMIC HEALTH (GHDX): Free Stock Analysis Report

ILLUMINA INC (ILMN): Free Stock Analysis Report

MYRIAD GENETICS (MYGN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MYGN GPS ANIP ILMN

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More